Generic Tambocor ( Flecainide )

Order cheap Generic Tambocor (Flecainide) without dr prescription in the United States

In our USA pharmacy, you can buy Tambocor without a prescription, with delivery across the USA within 2‑5 days. Discreet and anonymous packaging.
Tambocor (flecainide) is a Class IC antiarrhythmic agent used to prevent or treat serious heart rhythm disorders, including paroxysmal supraventricular tachycardia (PSVT), paroxysmal atrial fibrillation/flutter (PAF), and life‑threatening sustained ventricular tachycardia (VT). It works by blocking fast sodium channels in cardiac cells, which slows electrical conduction and stabilizes myocardial electrical activity.
Usual adult dose: For patients with paroxysmal supraventricular tachycardia (PSVT) or paroxysmal atrial fibrillation (PAF) without structural heart disease, the recommended starting dose is 50 mg orally every 12 hours. The dose may be increased in increments of 50 mg twice daily every 4 days until efficacy is achieved. For patients with sustained ventricular tachycardia (VT), the initial dose is 100 mg orally every 12 hours; the dose may be increased in increments of 50 mg twice daily every 4 days to a maximum of 400 mg per day.
Dosage form: Oral tablets (50 mg, 100 mg, 150 mg).
Onset of action: The peak plasma concentration is reached approximately 3 hours after oral administration; the antiarrhythmic effect begins within a few hours, with steady‑state concentrations achieved after 3‑5 days.
Duration of action: The elimination half‑life ranges from 12 to 27 hours (mean approximately 20 hours), supporting a 12‑hour dosing interval to maintain therapeutic levels.
Alcohol consumption should be limited; excessive alcohol intake may worsen heart rhythm disorders or increase the risk of side effects such as dizziness and liver dysfunction.
Most common side effects: dizziness, visual disturbances, shortness of breath, headache, nausea, and fatigue.
Would you like to try Tambocor without a prescription?

General Information about Tambocor

• INN (International Nonproprietary Name): Flecainide acetate
• Brand names available in the USA: Tambocor® (Alvogen). Generic versions are manufactured by Amneal Pharmaceuticals, Ani Pharmaceuticals, Aurobindo Pharma, Chartwell, Hikma Pharmaceuticals, Regcon Holdings, Sun Pharmaceutical Industries, and Yichang Humanwell.
• ATC code: C01BC04
• Dosage forms and strengths: Tablets for oral administration: 50 mg, 100 mg, and 150 mg.
• Manufacturers in USA: Alvogen (brand Tambocor®); generic manufacturers include Amneal Pharmaceuticals of New York LLC, Ani Pharmaceuticals, Aurobindo Pharma Ltd, Chartwell, Hikma Pharmaceuticals USA Inc., Regcon Holdings, Sun Pharmaceutical Industries Ltd, and Yichang Humanwell.
• Registration status in USA: Approved by the U.S. Food and Drug Administration (FDA) in 1984 (NDA 018830).
• OTC / Rx classification: Prescription only (Rx). DEA Schedule: None.

Mechanism of Action and Pharmacology

Flecainide acetate is a Class IC antiarrhythmic agent according to the Vaughan Williams classification. It exerts its therapeutic effect by potently blocking voltage‑gated fast sodium channels (Nav1.5) in cardiac myocytes and Purkinje fibers. By binding to the extracellular side of the sodium channel pore in its open state, flecainide slows the rapid influx of sodium ions during phase 0 of the cardiac action potential. This results in a dose‑dependent decrease in the maximum rate of depolarization (Vmax), thereby slowing conduction velocity throughout the myocardium. On the surface electrocardiogram (ECG), flecainide prolongs the PR interval and widens the QRS complex, with minimal or no effect on the QT interval (the JT interval is not prolonged). Flecainide also has local anesthetic (membrane‑stabilizing) activity. At very high concentrations, it exerts a weak depressant effect on the slow calcium channel in the myocardium, which is accompanied by a negative inotropic effect. Flecainide does not possess antimuscarinic (anticholinergic) activity and does not significantly prolong the action potential duration. After oral administration, flecainide is nearly completely absorbed (bioavailability approximately 90‑95%), with peak plasma concentrations reached in about 3 hours. It is approximately 40% bound to plasma proteins. Flecainide is metabolized extensively in the liver, primarily by cytochrome P450 2D6 (CYP2D6), with approximately 30% of the parent drug eliminated unchanged by the kidneys. The elimination half‑life averages 20 hours (range 12‑27 hours), permitting twice‑daily dosing. Steady‑state plasma concentrations are achieved within 3‑5 days.

Indications

• Prevention or treatment of paroxysmal supraventricular tachycardia (PSVT), including atrioventricular nodal re‑entrant tachycardia (AVNRT) and atrioventricular re‑entrant tachycardia (AVRT).
• Prevention or treatment of paroxysmal atrial fibrillation/flutter (PAF) in patients without structural heart disease.
• Prevention of life‑threatening sustained ventricular tachycardia (VT) in patients without structural heart disease when the benefits outweigh the risks.
• Off‑label uses: pharmacological cardioversion of recent‑onset atrial fibrillation, maintenance of sinus rhythm after cardioversion, and treatment of arrhythmias in specific populations such as patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) under specialist supervision.

Important Warnings and Precautions

Tambocor (flecainide) carries a black box warning regarding proarrhythmic effects, including provocation of new or worsened arrhythmias (ventricular tachycardia, ventricular fibrillation) and mortality. The Cardiac Arrhythmia Suppression Trial (CAST) demonstrated a 2.3‑fold increased risk of death or non‑fatal cardiac arrest in patients with prior myocardial infarction and reduced left ventricular ejection fraction (LVEF) who received flecainide compared with placebo. Flecainide is therefore contraindicated in patients with structural heart disease, including prior myocardial infarction, heart failure with reduced LVEF, and significant left ventricular hypertrophy. Flecainide should be initiated in a hospital setting for patients with sustained ventricular tachycardia and for high‑risk patients, where continuous ECG monitoring is available. Flecainide may cause new or worsening arrhythmias, particularly in patients with pre‑existing arrhythmias, electrolyte disturbances, or structural heart disease. It has a negative inotropic effect and can precipitate or worsen heart failure, especially in patients with reduced LVEF. Conduction disturbances, including AV block and bundle branch block, can occur. Flecainide increases the pacing and defibrillation thresholds; patients with pacemakers or implantable cardioverter‑defibrillators (ICDs) should be monitored. Brugada syndrome may be unmasked in susceptible patients. Hypokalemia or hypomagnesemia should be corrected before initiating therapy, as these electrolyte imbalances can potentiate proarrhythmic effects.

At‑risk groups

• Elderly: No specific dose adjustment based solely on age; however, elderly patients are more likely to have age‑related renal impairment, which may require dose reduction. Initiate at the lower end of the dosing range and monitor renal function.
• Pregnancy: There are no adequate and well‑controlled studies in pregnant women. Flecainide crosses the placenta. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus.
• Breastfeeding: Flecainide is excreted into human milk. Studies in breastfeeding women suggest that the medication poses minimal risk to the infant, but the infant should be monitored for adverse effects.
• Renal impairment: Flecainide is partially excreted unchanged by the kidneys (approximately 30%). In patients with significant renal impairment (creatinine clearance ≤35 mL/min/1.73 m²), the initial dose should not exceed 100 mg once daily (or 50 mg twice daily), and therapeutic drug monitoring is recommended.
• Hepatic impairment: Flecainide is extensively metabolized by the liver. Use with caution in patients with hepatic impairment; plasma level monitoring is recommended. The initial dose should be reduced.
• Pediatric: Appropriate studies have not been performed on the relationship of age to the effects of flecainide in the pediatric population. Safety and efficacy have not been established, but physicians may choose to use it in children with serious heart rhythm problems under specialist supervision.
• Structural heart disease: Contraindicated in patients with structural heart disease, including coronary artery disease with prior myocardial infarction, heart failure with reduced ejection fraction (LVEF <40%), and significant left ventricular hypertrophy, due to increased mortality risk demonstrated in the CAST trial.
• Conduction system disease: Contraindicated in patients with second‑ or third‑degree AV block, bifascicular or trifascicular block, or sick sinus syndrome unless a functioning pacemaker is present.

Driving and alcohol

Flecainide may cause dizziness, visual disturbances (blurred vision, difficulty focusing), and fatigue, which can impair the ability to drive or operate machinery. Patients should avoid driving or engaging in hazardous activities until they know how the medication affects them. Alcohol consumption should be limited. Excessive alcohol intake may worsen underlying arrhythmias, increase the risk of liver dysfunction, and exacerbate central nervous system side effects such as dizziness and drowsiness.

Dosage Instructions

• Paroxysmal supraventricular tachycardia (PSVT) and paroxysmal atrial fibrillation (PAF) in patients without structural heart disease: The recommended starting dose is 50 mg orally every 12 hours. The dose may be increased in increments of 50 mg twice daily every 4 days until efficacy is achieved. The maximum recommended dose is 300 mg per day (150 mg twice daily).
• Sustained ventricular tachycardia (VT) in patients without structural heart disease: The recommended starting dose is 100 mg orally every 12 hours. The dose may be increased in increments of 50 mg twice daily every 4 days until efficacy is achieved or adverse effects appear. The maximum recommended dose is 400 mg per day. Most patients with sustained VT do not require more than 150 mg every 12 hours (300 mg/day).
• Renal impairment: In patients with creatinine clearance ≤35 mL/min/1.73 m², the initial dose should not exceed 100 mg once daily (or 50 mg twice daily). Plasma level monitoring is strongly recommended.
• Hepatic impairment: Use with caution; initiate at the lower end of the dosing range and monitor plasma levels.
• Concomitant amiodarone: When flecainide is given in the presence of amiodarone, the usual flecainide dose should be reduced by 50%, and the patient should be monitored closely for adverse effects. Plasma level monitoring is strongly recommended.
• Administration: Flecainide may be taken with or without food. To minimize gastrointestinal irritation, taking it with food or milk is recommended. Tablets should be swallowed whole with a glass of water. The dose should be taken at approximately 12‑hour intervals.
• Missed dose: If a dose is missed, take it as soon as remembered. If it is almost time for the next scheduled dose, skip the missed dose and resume the regular schedule. Do not double the dose.
• Initiation of therapy: For patients with sustained VT, hospitalization for initiation of therapy is recommended with continuous ECG monitoring. For patients with PSVT or PAF without structural heart disease, initiation may be performed in an outpatient setting at the physician's discretion.

Side Effects and Contraindications

Most common adverse reactions (incidence >1%): Dizziness (10‑20%), visual disturbances (blurred vision, diplopia, difficulty focusing – 10‑20%), dyspnea (5‑10%), headache (5‑10%), nausea (5‑10%), fatigue (5‑10%), palpitations (3‑5%), chest pain (3‑5%), asthenia, tremor, and constipation. Most side effects are dose‑related and may resolve with dose reduction.
Serious adverse reactions: Proarrhythmic effects including new or worsened ventricular tachycardia, ventricular fibrillation, and torsades de pointes; heart failure or worsening of pre‑existing heart failure (due to negative inotropic effect); conduction disturbances including AV block, bundle branch block, and sinus node dysfunction; elevation of pacing and defibrillation thresholds; Brugada syndrome unmasking; hepatotoxicity including elevated liver enzymes, jaundice, and hepatitis; blood dyscrasias (leukopenia, thrombocytopenia, agranulocytosis – rare); and hypersensitivity reactions (rash, urticaria, angioedema).
CAST trial findings: In post‑myocardial infarction patients with reduced left ventricular ejection fraction, flecainide was associated with a 2.3‑fold increased risk of death or non‑fatal cardiac arrest compared with placebo, primarily due to arrhythmic death.
Absolute contraindications: Known hypersensitivity to flecainide or any excipient; structural heart disease including prior myocardial infarction, heart failure with reduced LVEF (<40%), and significant left ventricular hypertrophy; cardiogenic shock; second‑ or third‑degree AV block, bifascicular or trifascicular block, or sick sinus syndrome in the absence of a functioning pacemaker; concurrent use of ritonavir or other strong CYP2D6 inhibitors that significantly increase flecainide levels.

Drug Interactions

• CYP2D6 inhibitors (strong) (e.g., ritonavir, paroxetine, fluoxetine, bupropion, cinacalcet, duloxetine): Significant increase in flecainide plasma concentrations, increasing the risk of proarrhythmia and toxicity. Concomitant use with ritonavir is contraindicated. Other strong CYP2D6 inhibitors should be used with extreme caution; dose reduction and plasma level monitoring are recommended.
• CYP2D6 inducers (e.g., phenytoin, phenobarbital, carbamazepine): May decrease flecainide plasma concentrations, potentially reducing efficacy. Monitor for reduced therapeutic effect; dose increase may be necessary.
• Amiodarone: Increases flecainide plasma concentrations by approximately 50%. When used concomitantly, reduce the flecainide dose by 50% and monitor plasma levels closely.
• Other Class I antiarrhythmics (e.g., quinidine, procainamide, disopyramide, propafenone): Additive electrophysiologic effects and increased risk of proarrhythmia. Concomitant use should be avoided.
• Beta‑blockers (Class II antiarrhythmics) and calcium channel blockers (e.g., verapamil, diltiazem): Additive negative inotropic effects; caution is advised, particularly in patients with reduced left ventricular function. Monitor for signs of heart failure and bradycardia.
• Digoxin: Flecainide may increase digoxin plasma concentrations by approximately 15‑25%. Monitor digoxin levels and clinical response.
• Cimetidine: Increases flecainide AUC by approximately 30% and prolongs the elimination half‑life by approximately 10%. Dose adjustment may be necessary.
• Tricyclic antidepressants: Additive electrophysiologic effects; increased risk of arrhythmias. Avoid concomitant use when possible.
• Anticholinesterases (e.g., donepezil, rivastigmine, galantamine): Increased risk of bradycardia due to cumulative negative chronotropic effects. Clinical monitoring is required.
• Electrolyte‑depleting agents (e.g., diuretics causing hypokalemia, laxatives): Hypokalemia or hypomagnesemia may potentiate the proarrhythmic effects of flecainide. Monitor and correct electrolyte imbalances before and during therapy.
• Alcohol: Excessive alcohol intake may worsen arrhythmias and increase the risk of liver dysfunction. Limit alcohol consumption during therapy.

Practical Advice

• Take Tambocor exactly as prescribed, at the same times every day (usually every 12 hours). Taking the medication with food or milk may help minimize gastrointestinal irritation.
• Do not stop taking Tambocor suddenly without consulting your healthcare provider. Abrupt discontinuation may worsen your arrhythmia.
• If you miss a dose, take it as soon as you remember. If it is nearly time for your next scheduled dose, skip the missed dose. Do not take two doses at the same time to make up for a missed dose.
• Attend all scheduled follow‑up appointments. Your healthcare provider will need to monitor your heart rhythm with regular electrocardiograms (ECGs) to assess the effectiveness and safety of the medication. Periodic blood tests to check electrolytes, renal function, hepatic function, and flecainide plasma levels may be ordered.
• Report immediately to your healthcare provider any symptoms of new or worsening arrhythmia: fast, slow, or irregular heartbeat; palpitations; chest pain; shortness of breath; fainting or near‑fainting spells; or severe dizziness.
• Watch for signs of heart failure: swelling of the feet or ankles, rapid weight gain, worsening shortness of breath, or unusual fatigue. Report these symptoms promptly.
• Be alert for signs of liver toxicity: yellowing of the skin or whites of the eyes (jaundice), dark urine, pale stools, persistent nausea or vomiting, or right upper abdominal pain. Report these symptoms immediately.
• Use caution when driving or operating machinery until you know how Tambocor affects you. Dizziness and visual disturbances (blurred vision, trouble focusing) are common and can impair your ability to perform these activities safely.
• Limit alcohol consumption during treatment. Excessive alcohol intake may worsen your heart condition and increase the risk of side effects.
• Inform all healthcare providers (including dentists and surgeons) that you are taking flecainide, especially before any surgical procedure or if you require a pacemaker or ICD adjustment.
• Store at room temperature (15‑30°C / 59‑86°F) in a dry place, protected from light and moisture. Keep the container tightly closed and out of reach of children.
• Never share this medication with anyone else, even if they have similar symptoms. Tambocor is prescribed for a specific individual based on their cardiac condition and medical history.

Alternative Medications

• Propafenone (Rythmol®): Another Class IC antiarrhythmic agent with a similar mechanism of action (sodium channel blockade) and additional mild beta‑blocking activity. Used for PSVT, atrial fibrillation, and ventricular arrhythmias in patients without structural heart disease. Available in immediate‑release and extended‑release formulations.
• Sotalol (Betapace®, Betapace AF®, Sorine®): A Class III antiarrhythmic agent with additional Class II (beta‑blocking) activity. Prolongs repolarization and the QT interval. Used for atrial fibrillation and ventricular arrhythmias.
• Amiodarone (Pacerone®, Cordarone®): A Class III antiarrhythmic agent with a broad spectrum of activity across all Vaughan Williams classes. Highly effective for both atrial and ventricular arrhythmias but limited by significant long‑term toxicity affecting the thyroid, lungs, liver, skin, and eyes.
• Dronedarone (Multaq®): A Class III antiarrhythmic agent structurally related to amiodarone but with a better safety profile. Used for maintenance of sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Contraindicated in patients with heart failure.
• Dofetilide (Tikosyn®): A Class III antiarrhythmic agent that selectively blocks the rapid component of the delayed rectifier potassium current (IKr). Used for maintenance of sinus rhythm in atrial fibrillation and flutter. Requires initiation in a hospital setting with continuous ECG monitoring for the first 3 days.
• Catheter ablation: A non‑pharmacologic intervention involving radiofrequency or cryoablation of arrhythmogenic foci or circuits. Curative for many forms of PSVT and atrial flutter; increasingly used as first‑line therapy for atrial fibrillation.
• Beta‑blockers (e.g., metoprolol, atenolol, propranolol) and calcium channel blockers (e.g., verapamil, diltiazem): Used for rate control in atrial fibrillation and for prevention of PSVT. Less effective for rhythm control than Class I or Class III antiarrhythmics but with a more favorable safety profile.

Clinical Efficacy

The efficacy of flecainide for the prevention of paroxysmal supraventricular tachycardia (PSVT) and paroxysmal atrial fibrillation (PAF) was demonstrated in multiple placebo‑controlled clinical trials. In patients with PSVT, flecainide at doses of 50 mg to 150 mg twice daily reduced the frequency of symptomatic episodes by 70‑95%. For PAF, flecainide significantly prolonged the time to first recurrence of atrial fibrillation and reduced the overall arrhythmia burden. The Cardiac Arrhythmia Suppression Trial (CAST), published in 1991, was a landmark randomized, placebo‑controlled trial that evaluated the efficacy of flecainide (and encainide) for the suppression of asymptomatic or mildly symptomatic ventricular premature contractions (VPCs) in post‑myocardial infarction patients with reduced left ventricular ejection fraction. Although flecainide effectively suppressed VPCs, the trial was terminated prematurely due to a 2.3‑fold increased risk of death or non‑fatal cardiac arrest in the flecainide group compared with placebo. As a result, flecainide is now contraindicated in patients with structural heart disease. More recent observational studies and contemporary reappraisals suggest that flecainide may be safe and effective in specific populations with structural heart disease beyond the original CAST restrictions, including patients with stable coronary artery disease without active ischemia and preserved ventricular function, arrhythmogenic right ventricular cardiomyopathy (ARVC), and premature ventricular complex‑induced cardiomyopathy. The FLECA‑ED trial and other studies have shown that flecainide is effective for pharmacological cardioversion of recent‑onset atrial fibrillation in the emergency department setting, with high rates of conversion to sinus rhythm and shorter time to conversion compared with amiodarone. Flecainide remains a cornerstone of rhythm‑control therapy for patients with atrial fibrillation and other supraventricular arrhythmias who have structurally normal hearts.

Important:

Tambocor (flecainide) is a potent antiarrhythmic medication that must be used only under the supervision of a qualified healthcare provider, typically a cardiologist or electrophysiologist. This drug carries a black box warning for proarrhythmic effects and increased mortality in patients with structural heart disease, as demonstrated in the Cardiac Arrhythmia Suppression Trial (CAST). Flecainide is contraindicated in patients with prior myocardial infarction, heart failure with reduced ejection fraction, significant left ventricular hypertrophy, and other forms of structural heart disease. Initiation of therapy may require hospitalization with continuous ECG monitoring, particularly for patients with sustained ventricular tachycardia. Flecainide can cause new or worsened arrhythmias, including life‑threatening ventricular tachycardia and ventricular fibrillation. Regular monitoring of cardiac rhythm via electrocardiogram (ECG) is mandatory. Electrolyte imbalances (particularly low potassium or magnesium) must be corrected before and during therapy. Concomitant use of strong CYP2D6 inhibitors (e.g., ritonavir) is contraindicated, and caution is required with other CYP2D6 inhibitors, amiodarone, and drugs that slow cardiac conduction. Do not stop taking this medication suddenly without consulting your healthcare provider. Avoid driving or operating machinery until you know how flecainide affects you. Limit alcohol consumption during treatment. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the risks and benefits with their healthcare provider. Keep this medication out of reach of children and never share it with anyone else. If you experience symptoms such as fast or irregular heartbeat, chest pain, shortness of breath, fainting, severe dizziness, or signs of liver problems, seek immediate medical attention.

How to buy Generic Tambocor no prescription U.S. Online Pharmacy